A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.
Christian Michel ZwaanStefan SöderhällBenoit BrethonMatteo LucianiCarmelo RizzariRonald W StamEmmanuelle BesseCatherine DutreixFranca FagioliPhoenix A HoCarlo DufourRob PietersPublished in: British journal of haematology (2018)
Keyphrases
- open label
- clinical trial
- liver failure
- acute lymphoblastic leukemia
- young adults
- diffuse large b cell lymphoma
- phase ii
- respiratory failure
- phase ii study
- hodgkin lymphoma
- randomized controlled trial
- radiation therapy
- squamous cell carcinoma
- intensive care unit
- aortic dissection
- acute respiratory distress syndrome
- rectal cancer
- double blind